Rebus Holdings, Inc. (RBSH)
0.0000
0.00 (0.00%)
USD |
OTCM |
Aug 28, 16:00
Rebus Holdings Net Income (Quarterly)
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 0.043M |
| March 31, 2023 | -0.424M |
| December 31, 2022 | 0.635M |
| September 30, 2022 | 0.316M |
| June 30, 2022 | -1.365M |
| March 31, 2022 | -0.606M |
| December 31, 2021 | 0.052M |
| September 30, 2021 | 6.125M |
| June 30, 2021 | 17.16M |
| March 31, 2021 | -20.64M |
| December 31, 2020 | -6.50M |
| September 30, 2020 | 2.106M |
| June 30, 2020 | -1.175M |
| March 31, 2020 | -0.726M |
| December 31, 2019 | -0.442M |
| September 30, 2019 | 0.421M |
| June 30, 2019 | -0.838M |
| March 31, 2019 | -0.075M |
| December 31, 2018 | 2.197M |
| September 30, 2018 | -2.671M |
| June 30, 2018 | 0.718M |
| March 31, 2018 | -0.256M |
| December 31, 2017 | -5.459M |
| September 30, 2017 | -5.772M |
| June 30, 2017 | -0.821M |
| Date | Value |
|---|---|
| March 31, 2017 | -0.925M |
| December 31, 2016 | -1.354M |
| September 30, 2016 | -1.221M |
| June 30, 2016 | -0.49M |
| March 31, 2016 | -0.49M |
| December 31, 2015 | -1.137M |
| September 30, 2015 | -1.373M |
| June 30, 2015 | -1.532M |
| March 31, 2015 | -1.843M |
| December 31, 2014 | -1.656M |
| September 30, 2014 | -1.793M |
| June 30, 2014 | -1.605M |
| March 31, 2014 | -1.94M |
| December 31, 2013 | -2.056M |
| September 30, 2013 | -1.005M |
| June 30, 2013 | -0.944M |
| March 31, 2013 | -1.297M |
| December 31, 2012 | -1.296M |
| September 30, 2012 | -1.774M |
| June 30, 2012 | -0.8553M |
| March 31, 2012 | -2.994M |
| December 31, 2011 | -1.930M |
| September 30, 2011 | -1.739M |
| June 30, 2011 | -1.696M |
| March 31, 2011 | -0.3487M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |